Safer alternative sought for High-Risk pregnancy seizure drug
NCT ID NCT07220902
Summary
This study aims to see if a drug called levetiracetam works as well as the current standard, magnesium sulfate, to prevent life-threatening seizures in pregnant people with severe preeclampsia. It will enroll 1,240 participants who are at least 32 weeks pregnant. The main goal is to find out if the new option is just as effective while potentially having fewer side effects for both the mother and baby.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE PREECLAMPSIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Methodist Women's Hospital
Omaha, Nebraska, 68022, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.